Health Care

Celgene to Buy Receptos for About $7.2 Billion

Celgene Corp. has reached a deal to buy fellow biopharmaceutical company Receptos Inc. for about $7.2 billion, enhancing its portfolio of immune-inflammatory disease treatments with the addition of Ozanimod.

Americans Spending Less on Medicines

Patent expirations on big-name drugs such as Lipitor and Plavix has resulted in modestly less spending on medicines in the United States for the first time in at least 55 years, according to a report released on Thursday.

U.S. Drugmaker Turing to Roll Back 5,000% Price Hike

Turing Pharmaceuticals, a small company that generated outrage over raising the cost of an old anti-infective drug by more than 5,000%, said on Tuesday it would roll back that increase to make sure it remains affordable.

Amgen to Help Develop Novartis's Pipeline of Alzheimer's Drugs

Novartis AG will share the risks and rewards as Amgen Inc. will help develop its pipeline of experimental Alzheimer's disease drugs, in a move that is becoming increasingly commonplace among drug makers eager to address the difficult-to-treat condition.